[ExI] A new therapeutic approach improves the outcome of patients with (aging-related) COVID-19 Pneumonia

Ilia Stambler ilia.stambler at gmail.com
Sun Mar 8 03:33:33 UTC 2020

Dear friends
I would like to bring to your attention the press release by the
International Society on Aging and Disease (ISOAD), Shanghai University,
Chinese Academy of Medical Sciences & Peking Union Medical College, China:

A groundbreaking new therapeutic approach was developed and tested to
improve outcome in patients suffering from novel coronavirus (COVID-19)
pneumonia. The new technique involves intravenous transplantation of
mesenchymal stem cells (MSCs) into the patients. It was successfully tested
in 7 COVID-19 patients, in Beijing YouAn Hospital, Capital Medical
University, China. The results are published in the scientific journal *Aging
and Disease*, entitled "Transplantation of ACE2- Mesenchymal Stem Cells
Improves the Outcome of Patients with COVID-19 Pneumonia" (free on line):

The study was conducted by a team led by Dr. Zhao, with Shanghai University
and Chinese Academy of Medical Sciences & Peking Union Medical College,

MSCs could cure or significantly improve the functional outcomes of all the
seven tested patients without observed adverse effects, contrary to 3
controls. The pulmonary function and symptoms of these seven patients were
significantly improved after MSC transplantation. Among them, one severe
and two common patients recovered and were discharged in 10 days after the

The presented evidence suggests that the therapeutic effects are based on
the immunomodulatory capacity of mesenchymal stem cells (restoring the
balance of the immune system). The coronavirus infection can stimulate a
terrible cytokine storm in the lung, disrupting the balance of cytokines
(signaling molecules of the immune system) such as IL-2, IL-6, IL-7, GSCF,
IP10, MCP1, MIP1A and TNFα cytokines, followed by the edema, dysfunction of
the air exchange, acute respiratory distress syndrome, acute cardiac injury
and the secondary infection, which may lead to death. MSCs could inhibit
the over-activation of the immune system and promote endogenous repair by
improving the microenvironment, thus they could represent a safe and
effective treatment for patients with COVID-19 pneumonia, especially for
the patients in critically severe conditions.

Notably, the coronavirus-infected pneumonia is more likely to affect older
individuals, especially older males, with comorbidities, resulting in their
severe and even fatal respiratory diseases such as acute respiratory
distress syndrome. In other words, aging appears to be the main risk factor
for bad outcomes. However, the cure essentially depends on the patient's
own immune system. When the overactivated immune system kills the virus, it
produces a large number of inflammatory factors, leading to the severe
cytokine storms. This suggests that the main reason for the organs damage
may be the virus-induced cytokine storm. Older subjects may be much easier
to be affected due to immunosenescence. The study showed remarkable
recovery of the elderly patients thanks to restoring their immune function.

Thus, the study may have a broader significance, even beyond the treatment
of the severe coronavirus disease. This study exemplifies that the general
therapeutic improvement of the immune system in the elderly can improve
outcome and survival, which may have more general relevance for other
aging-related communicable diseases. Thus, this study may inspire and pave
the way for further promising directions to investigate the connection
between aging and disease, and to treat both communicable and
non-communicable aging-related diseases.

See the full press release from the International Society on Aging and
Disease (ISOAD)
And the full free article

Some press about this research:
In English http://www.china.org.cn/china/2020-03/07/content_75785868.htm
Korean https://www.fnnews.com/news/202003041842036630

On Facebook







Ilia Stambler
Outreach coordinator. International Society on Aging and Disease


Ilia Stambler, PhD

Director of Research and Development. Shmuel Harofe Geriatric Medical
Center, Beer Yaakov, Israel, Affiliated to Sackler School of Medicine,
Tel-Aviv University http://www.shmuelh.org.il/

Chair. Israeli Longevity Alliance / CSO. Vetek (Seniority) – The Movement
for Longevity and Quality of Life (Israel) *http://www.longevityisrael.org/

Board member. International Longevity Alliance
http://www.longevityalliance.org/ Board member. International Society on
Aging and Disease http://www.isoad.org Fellow, Policy Director. Global
Healthspan Policy Institute https://healthspanpolicy.org/

Author. Longevity History. *A History of Life-Extensionism in the Twentieth
Century *; *Longevity Promotion: Multidisciplinary Perspectives *

Email: ilia.stambler at gmail.com

Tel: 972-3-961-4296 / 0522-283-578

Skype: iliastam

Rishon Lezion. Israel
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.extropy.org/pipermail/extropy-chat/attachments/20200308/c56ea43c/attachment.htm>

More information about the extropy-chat mailing list